When was Genoptix founded?

Genoptix was founded in 1999 and raised its 1st funding round 3 years after it was founded.

Where is Genoptix located?

Genoptix is headquartered in Carlsbad, United States.

How many employees does Genoptix have?

As of Dec 31, 2018, Genoptix has 46 employees, reflecting a 91% year-over-year decline in headcount.

Is Genoptix a funded company?

Genoptix is a funded company, having raised a total of $33.3M across 7 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Nov 22, 2002.

When was the latest funding round of Genoptix?

Genoptix's latest funding was a $***** Series D round on Aug 10, 2005, with participation from 2 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.23B in funding in 2026 to date.

Where does Genoptix rank among its competitors?

Genoptix ranks 5th amongst 24 active competitors, of which 8 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Abingdon Health, which secured $4.4M in Oct, 2025.

Who are the top competitors of Genoptix?

Genoptix's top competitors include Abingdon Health, Precipio Diagnostics and SkylineDX. Among them, Abingdon Health secured the most recent funding round in October, 2025.

Genoptix - 2026 Company Profile, Team, Funding & Competitors

Q: Is Genoptix an acquired company?

Genoptix got acquired by NeoGenomics on Oct 23, 2018.

Genoptix is an acquired company based in Carlsbad (United States), founded in 1999 by Tina S Nova and Gene Tu. It operates as an Oncology diagnostics and informatics services. Genoptix has raised $33.3M in funding. The company has 24 active competitors, including 8 funded and 5 that have exited. Its top competitors include companies like Abingdon Health, Precipio Diagnostics and SkylineDX.

Company Details

Genoptix focussed on Oncology diagnostics and informatics services. It was the first licensee of AQUA technology (which it received by acquiring HistoRx) to perform clinical laboratory services for measurement of protein in tissue specimens. It has launched a series of breast cancer assays using this platform. It also provides comprehensive testing solutions to community oncologists and pathologists in hematology and solid tumor molecular profiling. It claims that it has the largest hematopathology center in US and is specialized in diagnosing cancers in bone marrow, blood and lymph nodes. It was acquired by Novartis in January 2011 for $470M and is currently serving as its subsidiary.

Website: genoptix.com
Social
Email ID: *****@genoptix.com
Phone Number: +1 **********

Key Metrics

Founded Year

1999

Location

Carlsbad, United States

Stage

Acquired

Total Funding

$33.3M in 7 rounds

Latest Funding Round

Series D, Aug 10, 2005, $*****

Investors

Comerica & 3 more

Ranked

5^th among 24 active competitors

Employee Count

46 as on Dec 31, 2018

Investment & Acquisitions

Rosetta Genomics & 1 more

Similar Companies

Abingdon Health & 28 more

Exit Details

Acquired by NeoGenomics (Oct 23, 2018)

View Genoptix's full profile

Genoptix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Genoptix, Inc. CIN: 330840570 , United States, Active	Dec 31, 1998	-	46 (As on Dec 31, 2018)	-

Genoptix got acquired by NeoGenomics on Oct 23, 2018 at an acquisition amount of $*****.

Click here to take a look at Genoptix's acquisition in detail

Genoptix has raised a total funding of $33.3M over 7 rounds. Its first funding round was on Nov 22, 2002. Its latest funding round was a Series D round on Aug 10, 2005 for $*****. 2 investors participated in its latest round. Genoptix has 4 institutional investors.

Here is the list of recent funding rounds of Genoptix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 10, 2005	6992673	Series D	4324251	4175528	9858147	4703932
Sep 24, 2004	5188855	Series C	1827893	8061189	5170184	5434441
Oct 28, 2003	9004654	Series B	8109431	1854113	9331163	4544364

Access funding benchmarks and valuations. Sign up today!

View details of Genoptix's funding rounds and investors

The founders of Genoptix are Tina S Nova and Gene Tu. Joseph Limber and Robert Curtis are the CEOs of Genoptix.

Here are the details of Genoptix's key team members:

Tina S Nova: Co-Founder of Genoptix.
Gene Tu: Co-Founder of Genoptix.
Robert Curtis: CEO of Genoptix.

View details of Genoptix's Founder profiles and Board Members

Genoptix's employee count trend

Genoptix has 46 employees as of Dec 18. The total employee count is 92.0% lower than what it was in Dec 17. Here is Genoptix's employee count trend over the years:

Uncover Genoptix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genoptix include Abingdon Health, Precipio Diagnostics and SkylineDX. Here is the list of Top 10 competitors of Genoptix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abingdon Health 2008, York (United Kingdom), Public	Developer of immunoassays for diagnostic purposes	$24.1M	Imperial Innovations, Mercia & 2 others	68/100
2nd	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Ironwood Capital, Enhanced Capital & 3 others	64/100
3rd	SkylineDX 2005, Rotterdam (Netherlands), Seed	Provider of gene expression profiling tests for personalized medicine	-	Novalis LifeSciences, Van Herk Groep & 5 others	54/100
4th	Biofluidica 2007, Chapel Hill (United States), Series B	Provider of liquid biopsy tests using CTCs	$18.1M	NIH, HHS & 1 others	47/100
5th	Genoptix 1999, Carlsbad (United States), Acquired	Oncology diagnostics and informatics services	$33.3M	Comerica, Tullis Health Investors & 2 others	46/100
6th	Plexision 2008, Pittsburgh (United States), Seed	Personalized diagnostics and drug development using cellular biomarkers for better health	$365K	Richard King Mellon Foundation, America’s Seed Fund ... Read more	46/100
7th	Invivoscribe 1995, San Diego (United States), Unfunded	Provider of molecular diagnostics for personalized medicine in oncology	-	-	46/100
8th	Elucida Oncology 2014, Santa Barbara (United States), Series B	Developer of a particle delivery platform using nanotechnology	$81.5M	Lynx Financial, ARTEFIN	42/100
9th	4D Lifetec 2014, Zug (Switzerland), Series C	Developer of a diagnostic test for genotoxicity to diagnose multiple cancers	$36.8M	Venturelab, Xlife sciences & 1 others	39/100
10th	Repertoire 2014, Ibaraki (Japan), Acquired	TCR/BCR repertoire analysis services	$6.47M	UTEC, Beyond Next Ventures	38/100